Skip to main content
Eutilex Co.,Ltd. logo

Eutilex Co.,Ltd. — Investor Relations & Filings

Ticker · 263050 ISIN · KR7263050007 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country KR South Korea
Listing KO 263050

About Eutilex Co.,Ltd.

https://www.eutilex.com/en/

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Recent filings

Filing Released Lang Actions
주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)
Regulatory Filings Classification · 65% confidence The document is a brief regulatory announcement about the change in the trading halt period for (주)유틸렉스 ordinary shares under KOSDAQ market rules. It does not present financial reports or meeting materials, nor is it a delisting notice per se, but a trading suspension update under listing regulations. Therefore it falls under the general regulatory filings fallback category.
2026-03-26 Korean
기타시장안내 (상장적격성 실질심사 대상 결정)
Delisting Announcement Classification · 95% confidence The document is a Korean stock exchange market notice (“기타시장안내”) stating that the company UtilX (유틸렉스) has been designated for a listing eligibility review under the KOSDAQ rules and outlining the timetable and procedures for possible delisting. This is an official delisting-related announcement. Therefore, it should be classified as a Delisting Announcement (Code: DLST).
2026-03-26 Korean
[기재정정]내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생
Regulatory Filings Classification · 85% confidence The document is a Korean Exchange (KRX) regulatory disclosure notifying investors of a corrected filing (‘정정신고’) regarding internal financial review leading to management item designation and formal delisting eligibility review. It is not the full annual or interim report, nor is it dividend, M&A or board change information. It is a correction to a prior regulatory announcement, making it a general regulatory filing (fallback category).
2026-03-25 Korean
사업보고서제출기한연장신고서 (2025.12)
Regulatory Filings Classification · 95% confidence The document is a formal 'Report Submission Deadline Extension Notice' (사업보고서제출기한연장신고서) filed by Eutilex Co., Ltd. It explains that the company is unable to meet the statutory deadline for filing its annual report due to delays in the audit process by its external auditor (Samjong KPMG). This document is a regulatory notification regarding filing compliance and does not constitute the annual report itself, nor is it a simple announcement of a report's availability. Given the specific nature of regulatory filings regarding reporting deadlines, it falls under the 'Regulatory Filings' category.
2026-03-19 Korean
기타경영사항(자율공시) (감사보고서 지연 제출)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Eutilex regarding the delay in submitting their audit report. It explains that the external auditor (Samjong KPMG) could not complete the audit procedures in time for the statutory deadline before the general meeting. This is a disclosure of a corporate event/regulatory status update rather than an audit report itself, a financial report, or a report publication announcement. Given it is a specific regulatory disclosure regarding audit status, 'RNS' (Regulatory Filings) is the most appropriate classification.
2026-03-19 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to provide shareholders with information regarding upcoming general meeting agenda items (such as director/auditor appointments, financial statement approval, and remuneration limits) to solicit their votes. This corresponds to the 'Proxy Solicitation & Information Statement' category.
2026-03-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.